C4 Therapeutics, Inc. (CCCC) Tops Q3 EPS by 3c

C4 Therapeutics, Inc. (NASDAQ: CCCC) reported Q3 EPS of ($0.35), $0.03 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $15.36 million versus the consensus estimate of $5.9 million.

For earnings history and earnings-related data on C4 Therapeutics, Inc. (CCCC) click here.

You May Also Be Interested In

• Movano (MOVE) Misses Q2 EPS by 195c
• Stripe, Advent In Talks To Buy Paypal - WSJ
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49